v3.26.1
Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue:        
Total revenue $ 4,050 $ 17,084 $ 12,362 $ 21,320
Operating expenses:        
Research and development [1] 45,987 39,213 92,649 81,711
Sales, general, and administrative [1] 13,850 21,986 26,185 41,054
Depreciation and amortization 6,990 5,470 13,828 10,801
Total operating expenses 66,827 66,669 132,662 133,566
Loss from operations (62,777) (49,585) (120,300) (112,246)
Other (income) expense:        
Interest and other 42 (9,549) (3,606) (15,073)
Grants and incentives (3,854) (3,692) (8,193) (7,845)
Total other income (3,812) (13,241) (11,799) (22,918)
Loss before income tax (58,965) (36,344) (108,501) (89,328)
Income tax recovery (3,538) (1,617) (9,909) (8,980)
Net loss (55,427) (34,727) (98,592) (80,348)
Foreign currency translation adjustment (733) 4,341 1,082 1,721
Comprehensive loss $ (56,160) $ (30,386) $ (97,510) $ (78,627)
Net loss per share        
Basic (in dollars per share) $ (0.18) $ (0.12) $ (0.32) $ (0.27)
Diluted (in dollars per share) $ (0.18) $ (0.12) $ (0.32) $ (0.27)
Weighted-average common shares outstanding        
Basic (in shares) 305,557,294 298,508,601 304,329,623 298,105,760
Diluted (in shares) 305,557,294 298,508,601 304,329,623 298,105,760
Research fees        
Revenue:        
Total revenue $ 3,901 $ 6,639 $ 12,021 $ 10,707
Licensing and royalty revenue        
Revenue:        
Total revenue $ 149 $ 10,445 $ 341 $ 10,613
[1] Exclusive of depreciation and amortization